Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

PREcision MEDicine In Achalasia (PREMEDIA) (PREMEDIA)

10 de noviembre de 2026 actualizado por: John Pandolfino, Northwestern University

PREcision MEDicina en Acalasia - Un Ensayo Clínico Multicéntrico Aleatorizado de No Inferioridad de POEM Adaptado Corto vs. POEM Estándar para Acalasia No Espástica y Un Estudio de Cohorte Prospectivo Multicéntrico de POEM Adaptado Largo para Trastornos de Motilidad Esofágica Espástica

The goal of this clinical trial is to learn if shorter Per-Oral Endoscopic Myotomy (POEM) works as well as a longer POEM in patients with trouble swallowing due to certain conditions. The main question[s] it aims to answer [is/are]:

  • Does making a smaller cut in the muscle at the bottom of the esophagus work just as well as making the standard bigger cut in relieving symptoms?
  • Does making the smaller cut reduce the side effects of the procedure compared to the standard bigger cut? Researchers will compare the symptoms and side effects of making a shorter cut to the symptoms and side effects of a longer cut.

Participants will allow researchers to access their standard of care information in their medical record, complete questionnaires at up to 6 times over a 2-year period.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

The investigators will perform a randomized controlled trial to compare two different approaches to Peroral Endoscopic Myotomy (POEM) for treating achalasia (Types I and II) and esophagogastric junction outflow obstruction (EGJOO). The most widely used treatment for achalasia is POEM but the current approach involves a 9 cm (3.5 inch) myotomy (cutting of the muscle) to open up the tight lower esophageal sphincter to promote food delivery from the esophagus to the stomach. This approach is very effective, with success rates of approximately 90% over the short term. However, the investigators believe that POEM does not require a full 9 cm myotomy and that the investigators can cut much less muscle (approximately 4cm/1.25inches) to achieve similar improvement in symptoms but with less long-term complications. Cutting less muscle may result in less acid reflux, which is the Achilles heel of any successful treatment for achalasia. A shorter muscle cut may also result in less of a complication known as blown-out myotomy, which causes failure of the esophagus to empty its contents and is a major cause of long-term symptom relapse. The investigators have designed this study to determine whether the shorter myotomy (4 cm) is equivalent to the longer myotomy (9 cm) in terms if symptom improvement, but with the possibility of less acid reflux and blown-out myotomy.

Given these questions, the investigators will enroll 370 patients in a randomized trial where patients will receive either the short tailored (4cm/1.25 inches) or the standard myotomy (9cm/3.5 inches). All patients will undergo intraoperative assessment of success of the myotomy by using a special tool called the functional lumen imaging probe (FLIP). The FLIP will measure the opening dimensions of the lower esophageal sphincter and ensure that the myotomy is adequately performed so that the lower esophageal sphincter can open to a level that will improve esophageal emptying/swallowing. The investigators will follow patients for 2 years in a manner similar to how the investigators would follow patients after achalasia treatment in standard clinical practice. The investigators will assess whether symptoms are similar and whether or not there are differences in acid reflux and esophageal emptying. Patients will undergo follow up testing with questionnaires at intervals of 3-6 months over two years and they will have reflux testing (measure acid exposure using a capsule placed during endoscopy) between 6-12 months and a barium esophagram (X ray while drinking barium) at 2 years. The most important aim is to prove that the symptoms and outcomes success/failure) between the two approaches are similar (short myotomy is non-inferior) and the Eckardt score will be the primary questionnaire score for this study. The investigators believe that this study will help define the optimal approach to POEM in achalasia and also help us prevent complications in the future.

Additionally, the investigators will also ask participants to provide a sample of the muscle tissue that is typically cut during the POEM. This tissue will help us develop a tissue bank to help other researchers looking into the causes of why achalasia and these other esophageal diseases occur. The participants can opt out of this part and still continue in the randomized controlled trial.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

372

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

    • Arizona
      • Scottsdale, Arizona, Estados Unidos, 85259
        • Aún no reclutando
        • Mayo Clinic Arizona
    • California
      • La Jolla, California, Estados Unidos, 92037
        • Reclutamiento
        • University of California San Diego
        • Investigador principal:
          • Rena Yadlapati, MD
        • Contacto:
          • Alexander Gonsalves, Lead Study Coordinator
          • Número de teléfono: 858-246-5236
          • Correo electrónico: PREMEDIA@health.ucsd.edu
    • Colorado
      • Denver, Colorado, Estados Unidos, 80217
        • Aún no reclutando
        • University of Colorado Denver
    • Florida
      • Gainesville, Florida, Estados Unidos, 32611
        • Reclutamiento
        • University of Florida
        • Investigador principal:
          • Peter Draganov, MD
        • Contacto:
      • Orlando, Florida, Estados Unidos, 32803
        • Aún no reclutando
        • Adventist Health System/Sunbelt, Inc
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30322
        • Reclutamiento
        • Emory University
        • Investigador principal:
          • Anand Jain, MD
        • Contacto:
          • Halley Fowler, Lead Study Coordinator
          • Número de teléfono: 404-778-3184
          • Correo electrónico: halley.fowler@emory.edu
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60611
        • Reclutamiento
        • Northwestern University
        • Investigador principal:
          • John Pandolfino, MD
        • Contacto:
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21218
        • Aún no reclutando
        • Johns Hopkins University
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02114
        • Reclutamiento
        • Massachusetts General Hospital
        • Contacto:
          • Madison Paylor, Lead Study Coordinator
          • Número de teléfono: 617-726-0196
          • Correo electrónico: premedia@mgb.org
        • Investigador principal:
          • Kyle Staller, MD
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63110
        • Reclutamiento
        • Washington University
        • Contacto:
        • Investigador principal:
          • Chandra Gyawali, MD
    • New York
      • New York, New York, Estados Unidos, 10065
        • Aún no reclutando
        • Weill Cornell Medical College
    • North Carolina
      • Charlotte, North Carolina, Estados Unidos, 28204
        • Reclutamiento
        • Atrium Health/Wake Forest
        • Investigador principal:
          • Badih Elmunzer, MD
        • Contacto:
    • Ohio
      • Cleveland, Ohio, Estados Unidos, 44109
        • Reclutamiento
        • MetroHealth Medical Center
        • Investigador principal:
          • Ronnie Fass, MD
        • Contacto:
          • Stephanie Baker, Lead Study Coordinator
          • Número de teléfono: 216-778-5736
          • Correo electrónico: premedia@metrohealth.org
      • Cleveland, Ohio, Estados Unidos, 44106
        • Aún no reclutando
        • Case Western Reserve University
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37232
        • Reclutamiento
        • Vanderbilt University Medical Center
        • Investigador principal:
          • Dhyanesh Patel, MD
        • Contacto:
          • Larry Raber, Lead Study Coordinator
          • Número de teléfono: 615-322-4643
          • Correo electrónico: larry.w.raber@vumc.org
    • Texas
      • Dallas, Texas, Estados Unidos, 75246
        • Reclutamiento
        • Baylor Scott & White Health
        • Contacto:
          • Neomy Flores, Lead Study Coordinator
          • Número de teléfono: 214-820-9704
          • Correo electrónico: premedia@bswhealth.org
        • Investigador principal:
          • Vani Albertson Konda, MD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria

  1. Age ≥ 18
  2. Type I achalasia or type II achalasia or cEGJOO
  3. Eckardt score > 3

Exclusion Criteria

The following exclusion criteria are for the RCT, but 1-13 below also pertain to the observational study:

  1. Prior POEM
  2. Prior surgical treatment for achalasia
  3. Endoscopic pneumatic dilation or lower esophageal sphincter botulinum toxin (botox) injection within 6 months
  4. Prior unrelated esophageal or upper gastric surgery, including Roux-en-Y gastric bypass and sleeve gastrectomy
  5. Prior endoscopic gastroesophageal intervention for obesity or GERD, such endoscopic sleeve gastroplasty or transoral incisionless fundoplication
  6. Known secondary achalasia related to malignancy (pseudoachalasia)
  7. Known eosinophilic esophagitis
  8. Diverticulum (> 2 cm) in distal esophagus
  9. Megaesophagus
  10. Fibroinflammatory stricture of the esophagus due to any etiology (e.g., peptic, radiation, eosinophilic)
  11. Pregnancy
  12. Standard contraindications to general anesthesia
  13. Standard contraindications to endoscopic myotomy in the esophagus (e.g. untreated varices)
  14. Unwillingness or inability to consent for the study
  15. Anticipated inability to follow protocol
  16. Weekly (or more frequent) opioid medication use in the last 2 years

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Miotomía Estándar

Myotomy during POEM of 8-10 cm in length, extending 2-3 cm into the gastric cardia; intention to perform selective circular myotomy, but allowing full thickness myotomy. FLIP is used to confirm adequate myotomy.

Experimental: Miotomía Corta Personalizada

Myotomy during POEM of 4-5 cm in length, extending 1-2 cm into the gastric cardia; intend to perform selective circular myotomy, but allowing full thickness myotomy. FLIP is used to confirm adequate myotomy.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Clinical Response-Overall
Periodo de tiempo: From enrollment to Year 2

Clinical Response is defined by the Eckardt score (a 4-item self-report scale measuring weight loss, chest pain, regurgitation, and dysphagia) with no need for retreatment in 2 years.

From enrollment to Year 2
Clinical Response-by Sex
Periodo de tiempo: From enrollment to Year 2

Clinical Response is defined by the Eckardt score (a 4-item self-report scale measuring weight loss, chest pain, regurgitation, and dysphagia) with no need for retreatment in 2 years.

From enrollment to Year 2
Clinical Response-by Race
Periodo de tiempo: From Enrollment to Year 2

Clinical Response is defined by the Eckardt score (a 4-item self-report scale measuring weight loss, chest pain, regurgitation, and dysphagia) with no need for retreatment in 2 years.

From Enrollment to Year 2
Clinical Response-by Ethnicity
Periodo de tiempo: From Enrollment to Year 2

Clinical Response is defined by the Eckardt score (a 4-item self-report scale measuring weight loss, chest pain, regurgitation, and dysphagia) with no need for retreatment in 2 years.

From Enrollment to Year 2

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

29 de abril de 2026

Finalización primaria (Estimado)

1 de agosto de 2031

Finalización del estudio (Estimado)

1 de agosto de 2032

Fechas de registro del estudio

Enviado por primera vez

17 de diciembre de 2025

Primero enviado que cumplió con los criterios de control de calidad

17 de diciembre de 2025

Publicado por primera vez (Actual)

19 de diciembre de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

12 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Palabras clave

Otros números de identificación del estudio

  • PREMEDIA (Pro00083748) - 01

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • RSC

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .